Advertisement
Advertisement
U.S. Markets open in 2 hrs 54 mins
Advertisement
Advertisement
Advertisement
Advertisement

Annexon, Inc. (ANNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.28+0.10 (+1.62%)
At close: 04:00PM EDT
6.25 -0.03 (-0.48%)
After hours: 05:45PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.18
Open6.28
Bid0.00 x 1000
Ask0.00 x 800
Day's Range6.01 - 6.36
52 Week Range2.06 - 22.33
Volume67,864
Avg. Volume203,509
Market Cap240.994M
Beta (5Y Monthly)0.21
PE Ratio (TTM)N/A
EPS (TTM)-3.04
Earnings DateNov 07, 2022 - Nov 11, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est21.75
  • GlobeNewswire

    Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

    BRISBANE, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced that it has granted equity inducement awards to three new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on September 15, 2022, in accor

  • GlobeNewswire

    Annexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results

    Advancing Robust Pipeline of Five Clinical-Stage Product Candidates Following ANX105 and ANX1502 Phase 1 Trial Initiations Multiple Clinical Readouts Anticipated throughout 2022 and 2023 Operating Runway into the Second Half of 2025 Following $130 Million Private Placement BRISBANE, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoim

  • GlobeNewswire

    Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025

    Proceeds Support Advancement of Broad Pipeline of Novel Complement Product Candidates for Diseases of the Body, Brain and EyeBRISBANE, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced the closing of its private placement, resulting in gross proceeds of approximately

Advertisement
Advertisement